How the brain immune protein CLEC7A may affect Alzheimer's
Official title: CLEC7A in microglia biology and Alzheimer's disease
Funded at University of Virginia · NIH-11457046 · Data updated 2026-11-12
Researchers are testing whether changing a brain immune protein called CLEC7A can help brain immune cells clear Alzheimer’s plaques for people with or at risk for Alzheimer’s disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Virginia NIH-funded |
| Lab location | 1 site (Charlottesville, United States) |
| Project start | April 1, 2023 |
| Project end | March 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $551,738 |
| NIH project number | 4R01AG078684-02 |
| Project ID | NIH-11457046 on NIH RePORTER |
Who could benefit from this research
✓Could help
This research is most relevant to people living with Alzheimer’s disease or those at high risk who are interested in future therapies that target brain immune cells.
✕Less likely to help
People without Alzheimer’s or those seeking an immediate treatment are unlikely to receive direct benefit from this lab-focused research.
What this research studies
From my point of view, the team is studying a protein called CLEC7A that is active in brain immune cells (microglia) and seems linked to Alzheimer’s. They use lab models of Alzheimer’s (including mice that develop amyloid plaques) to see what happens when CLEC7A is removed or activated, and they measure plaque levels and nerve cell health. The researchers also give a fungal-derived CLEC7A activator in the brain to see if boosting CLEC7A helps microglia clear amyloid. Results may suggest new ways to target microglia to reduce amyloid and protect neurons, which could guide future treatments for people.
Why it matters
Potential benefit: If successful, this work could point to new ways to boost brain immune cells to remove amyloid and potentially slow Alzheimer’s progression.
How similar studies have gone: Other animal studies have shown that altering microglial receptors can change amyloid clearance, but targeting CLEC7A is a newer approach with promising early results in mice.
Where this research is happening
-
University of Virginia
Charlottesville, United States Active
Researchers
- Principal investigator: Lukens, John R — University of Virginia
- Study coordinator: Lukens, John R
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.